Chiara Biosciences is revolutionizing Targeted Protein Degradation (TPD) with its proprietary CURE-PRO (Combinatorial Ubiquitination REal-time PROteolysis) platform. CURE-PROs are small-molecule degraders that self-assemble inside cells using novel linker chemistry—one molecule engages an E3 ligase and another engages the target protein. This approach enables oral administration, enhanced cell/tissue penetration, and central nervous system accessibility.
Chiara’s unique combinatorial strategy supports a high-throughput, reusable platform for developing both an internal pipeline and collaborative solutions for strategic CURE-PRO development. See www.chiarabio.com to learn more.
Company Details
- Employees
- 7
- Founded
- 2024
- Address
- Denver, Colorado, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.chiarabio.com
- Keywords
- Asha Therapeutics.
- HQ
- Denver, Colorado
Chiara Biosciences Questions
Chiara Biosciences's website is http://www.chiarabio.com
Chiara Biosciences's LinkedIn profile is https://www.linkedin.com/company/chiara-biosciences
Chiara Biosciences has
7 employees.
View email and phone details for 7
employees at Chiara Biosciences.
Chiara Biosciences's industry is
Biotechnology Research
Chiara Biosciences's top competitors are
Kura Oncology, Inc.,
Saccharo Inc.,
Pmv Pharmaceuticals, Inc.,
Encapsulate,
Gals Bio Ltd,
Asha Therapeutics,
Singular Immune,
Nomocan Pharmaceuticals,
Museum Of Medicine And Biomedical Discovery,
Aveo Oncology.
Chiara Biosciences's categories are Biotechnology Research
Chiara Biosciences's founding year is 2024
